Endo International plc [ENDP] stock Downgrade by Piper Sandler analyst, price target now $1


Endo International plc [NASDAQ: ENDP] traded at a low on 07/22/22, posting a -6.46 loss after which it closed the day’ session at $0.40. The company report on July 15, 2022 that Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Endo affiliate, Paladin Labs, will commercialize Quoin’s lead asset for Netherton Syndrome in Canada.

Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has entered into the License and Distribution Agreement and the Supply Agreement with Endo Ventures Limited, a subsidiary of Endo International plc (NASDAQ:ENDP), for the development, registration, supply, commercialization and distribution of QRX003, Quoin’s lead product for Netherton Syndrome, on an exclusive basis in Canada.

The results of the trading session contributed to over 12522814 shares changing hands. Over the past one week, the price volatility of Endo International plc stands at 8.55% while the volatility over the past one month is 22.39%.

The market cap for ENDP stock reached $97.14 million, with 233.88 million shares outstanding and 233.27 million shares in the current float. Compared to the average trading volume of 43.19M shares, ENDP reached a trading volume of 12522814 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Endo International plc [ENDP]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ENDP shares is $1.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ENDP stock is a recommendation set at 3.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Endo International plc shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on May 06, 2022. While these analysts kept the previous recommendation, Barclays dropped their target price from $5 to $2. The new note on the price target was released on March 02, 2022, representing the official price target for Endo International plc stock. Previously, the target price had yet another drop from $10 to $3, while Piper Sandler kept a Neutral rating on ENDP stock.

The Average True Range (ATR) for Endo International plc is set at 0.08, with the Price to Sales ratio for ENDP stock in the period of the last 12 months amounting to 0.03. Price to Free Cash Flow for ENDP in the course of the last twelve months was 0.34 with Quick ratio for the last quarter at 1.60.

How has ENDP stock performed recently?

Endo International plc [ENDP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.98. With this latest performance, ENDP shares gained by 12.19% in over the last four-week period, additionally sinking by -87.83% over the last 6 months – not to mention a drop of -91.74% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENDP stock in for the last two-week period is set at 42.39, with the RSI for the last a single of trading hit 42.75, and the three-weeks RSI is set at 40.26 for Endo International plc [ENDP]. The present Moving Average for the last 50 days of trading for this stock 0.5189, while it was recorded at 0.4154 for the last single week of trading, and 2.8357 for the last 200 days.

Endo International plc [ENDP]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Endo International plc [ENDP] shares currently have an operating margin of +25.45 and a Gross Margin at +59.21. Endo International plc’s Net Margin is presently recorded at -19.01.

Endo International plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.80.

Insider trade positions for Endo International plc [ENDP]

There are presently around $78 million, or 76.90% of ENDP stock, in the hands of institutional investors. The top three institutional holders of ENDP stocks are: BLACKROCK INC. with ownership of 37,704,517, which is approximately 2.38% of the company’s market cap and around 0.50% of the total institutional ownership; VANGUARD GROUP INC, holding 28,377,446 shares of the stock with an approximate value of $11.46 million in ENDP stocks shares; and PAULSON & CO. INC., currently with $7.0 million in ENDP stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Endo International plc stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 85 institutional holders increased their position in Endo International plc [NASDAQ:ENDP] by around 21,395,564 shares. Additionally, 101 investors decreased positions by around 17,130,786 shares, while 45 investors held positions by with 154,595,914 shares. The mentioned changes placed institutional holdings at 193,122,264 shares, according to the latest SEC report filing. ENDP stock had 23 new institutional investments in for a total of 2,399,576 shares, while 31 institutional investors sold positions of 2,409,387 shares during the same period.